Successful Ixazomib Treatment for Relapsed and Refractory Acute Myeloid Leukemia Transformed from Myelodysplastic Syndrome

Overview

Journal Clin Case Rep

Date 2021 Jul 1

PMID 34194792

Citations 2

Authors

Satoko Oka

Kazuo Ono

Affiliations

Soon will be listed here.

Abstract

Elevated NF-kB levels have been identified in primitive bone marrow cells from patients with MDS/AML, suggesting NF-kB as a therapeutic target in MDS/AML. We herein describe an MDS patient ineligible for SCT who, following treatment with azacitidine and bortezomib, transformed to leukemia, but maintained complete remission after monotherapy with ixazomib.

Citing Articles

Bortezomib Eliminates Persistent Infection through Rapid and Specific Host Cell Apoptosis.

Itoh R, Kurihara Y, Yoshimura M, Hiromatsu K Int J Mol Sci. 2022; 23(13).

PMID: 35806436 PMC: 9267172. DOI: 10.3390/ijms23137434.

Successful ixazomib treatment for relapsed and refractory acute myeloid leukemia transformed from myelodysplastic syndrome.

Oka S, Ono K Clin Case Rep. 2021; 9(6):e04287.

PMID: 34194792 PMC: 8222761. DOI: 10.1002/ccr3.4287.

References

Moreau P, Richardson P, Cavo M, Orlowski R, San Miguel J, Palumbo A . Proteasome inhibitors in multiple myeloma: 10 years later. Blood. 2012; 120(5):947-59. PMC: 4123429. DOI: 10.1182/blood-2012-04-403733. View

Attar E, Johnson J, Amrein P, Lozanski G, Wadleigh M, DeAngelo D . Bortezomib added to daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine for consolidation in patients with previously untreated acute myeloid leukemia age 60 to 75 years: CALGB (Alliance) study 10502. J Clin Oncol. 2012; 31(7):923-9. PMC: 3577952. DOI: 10.1200/JCO.2012.45.2177. View

Richardson P, Baz R, Wang M, Jakubowiak A, Laubach J, Harvey R . Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients. Blood. 2014; 124(7):1038-46. PMC: 4574453. DOI: 10.1182/blood-2014-01-548826. View

Mossner M, Jann J, Nowak D, Platzbecker U, Giagounidis A, Gotze K . Prevalence, clonal dynamics and clinical impact of TP53 mutations in patients with myelodysplastic syndrome with isolated deletion (5q) treated with lenalidomide: results from a prospective multicenter study of the german MDS study group (GMDS). Leukemia. 2016; 30(9):1956-9. DOI: 10.1038/leu.2016.111. View

Liu S, Liu Z, Xie Z, Pang J, Yu J, Lehmann E . Bortezomib induces DNA hypomethylation and silenced gene transcription by interfering with Sp1/NF-kappaB-dependent DNA methyltransferase activity in acute myeloid leukemia. Blood. 2007; 111(4):2364-73. PMC: 2234064. DOI: 10.1182/blood-2007-08-110171. View

Kumar S, Bensinger W, Zimmerman T, Reeder C, Berenson J, Berg D . Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma. Blood. 2014; 124(7):1047-55. PMC: 4468583. DOI: 10.1182/blood-2014-01-548941. View

Horiike S, Misawa S, Kaneko H, Kobayashi M, Nakao M, Nakagawa H . International prognostic scoring system and TP53 mutations are independent prognostic indicators for patients with myelodysplastic syndrome. Br J Haematol. 2001; 115(2):309-12. DOI: 10.1046/j.1365-2141.2001.03073.x. View

Oka S, Ono K . Successful ixazomib treatment for relapsed and refractory acute myeloid leukemia transformed from myelodysplastic syndrome. Clin Case Rep. 2021; 9(6):e04287. PMC: 8222761. DOI: 10.1002/ccr3.4287. View

Liesveld J, Rosell K, Bechelli J, Lu C, Messina P, Mulford D . Proteasome inhibition in myelodysplastic syndromes and acute myelogenous leukemia cell lines. Cancer Invest. 2011; 29(7):439-50. PMC: 4557209. DOI: 10.3109/07357907.2011.590567. View

10.

Greenberg P, Young N, Gattermann N . Myelodysplastic syndromes. Hematology Am Soc Hematol Educ Program. 2002; :136-61. DOI: 10.1182/asheducation-2002.1.136. View

11.

Daher M, Hidalgo Lopez J, Randhawa J, Jabbar K, Wei Y, Pemmaraju N . An exploratory clinical trial of bortezomib in patients with lower risk myelodysplastic syndromes. Am J Hematol. 2017; 92(7):674-682. PMC: 5580683. DOI: 10.1002/ajh.24746. View

12.

Richardson P . Update on proteasome inhibitors in multiple myeloma. Clin Adv Hematol Oncol. 2014; 12(3):179-81. View

13.

Advani A, Cooper B, Visconte V, Elson P, Chan R, Carew J . A Phase I/II Trial of MEC (Mitoxantrone, Etoposide, Cytarabine) in Combination with Ixazomib for Relapsed Refractory Acute Myeloid Leukemia. Clin Cancer Res. 2019; 25(14):4231-4237. PMC: 6635077. DOI: 10.1158/1078-0432.CCR-18-3886. View

14.

Dohner H, Estey E, Amadori S, Appelbaum F, Buchner T, Burnett A . Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2009; 115(3):453-74. DOI: 10.1182/blood-2009-07-235358. View

15.

Braun T, Carvalho G, Coquelle A, Vozenin M, Lepelley P, Hirsch F . NF-kappaB constitutes a potential therapeutic target in high-risk myelodysplastic syndrome. Blood. 2005; 107(3):1156-65. DOI: 10.1182/blood-2005-05-1989. View

16.

Reece D, Song K, Fu T, Roland B, Chang H, Horsman D . Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13. Blood. 2009; 114(3):522-5. DOI: 10.1182/blood-2008-12-193458. View

17.

Dimopoulos M, Kastritis E, Christoulas D, Migkou M, Gavriatopoulou M, Gkotzamanidou M . Treatment of patients with relapsed/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of cytogenetic abnormalities and of previous therapies. Leukemia. 2010; 24(10):1769-78. DOI: 10.1038/leu.2010.175. View

18.

Garcia J, Huang M, Medeiros B, Mitchell B . Selective Toxicity of Investigational Ixazomib for Human Leukemia Cells Expressing Mutant Cytoplasmic NPM1: Role of Reactive Oxygen Species. Clin Cancer Res. 2015; 22(8):1978-88. DOI: 10.1158/1078-0432.CCR-15-1440. View

19.

Byrd J, Mrozek K, Dodge R, Carroll A, Edwards C, Arthur D . Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood. 2002; 100(13):4325-36. DOI: 10.1182/blood-2002-03-0772. View

20.

Csizmar C, Kim D, Sachs Z . The role of the proteasome in AML. Blood Cancer J. 2016; 6(12):e503. PMC: 5223148. DOI: 10.1038/bcj.2016.112. View